Objective: The current study aimed to compare the renal effects of Empagliflozin with Linagliptin combined with Metformin in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease. combined with Metformin in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease. Materials and Methods: We conducted a randomized clinical trial on diabetic patients aged over 18 years with chronic renal failure and an EGFR between 20 to 60 ml/minutes/1.73 m2 corrected with the MDRD equation. Between January and December 2023, a total of 150 cases in Imam Hossein Hospital were randomized into two study arms of 75 cases receiving Empagliflozin (10 mg/day) and metformin or Linagliptin (5mg/day) and metformin for 6 months. The primary outcome was a change in chronic kidney disease (CKD) stage, while serum creatinine, fasting blood sugar (FBS), proteinuria, and blood pressure were evaluated at baseline, 3 and 6 months later. Results: The mean age of participants was 62.20 (± 4.45) years and 50% of them were females. Study indices including serum creatinine (P: 0.001), estimated glomerular filtration rate (eGFR) (P: 0.001), FBS (P: 0.001), HgA1c (P: 0.001), proteinuria (P: 0.001), and blood pressure (P: 0.001) reduced significantly over time in both groups. After adjustment for potential confounders, Empagliflozin reduced the level of serum creatinine independent of other factors. Conclusion: Empagliflozin significantly reduces the level of serum creatinine compared to Linagliptin in patients with T2DM and chronic renal failure.
{"title":"A Comparison of Renal Effects between Empagliflozin and Linagliptin in Diabetic Patients with Chronic Kidney Disease: A Randomized Clinical Trial","authors":"Reza Zeinabadi Noghabi, Rojin Rouintan, Tahereh Sabaghian, Shayesteh Khalili","doi":"10.18502/ijdo.v16i2.15706","DOIUrl":"https://doi.org/10.18502/ijdo.v16i2.15706","url":null,"abstract":"Objective: The current study aimed to compare the renal effects of Empagliflozin with Linagliptin combined with Metformin in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease. combined with Metformin in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease. \u0000Materials and Methods: We conducted a randomized clinical trial on diabetic patients aged over 18 years with chronic renal failure and an EGFR between 20 to 60 ml/minutes/1.73 m2 corrected with the MDRD equation. Between January and December 2023, a total of 150 cases in Imam Hossein Hospital were randomized into two study arms of 75 cases receiving Empagliflozin (10 mg/day) and metformin or Linagliptin (5mg/day) and metformin for 6 months. The primary outcome was a change in chronic kidney disease (CKD) stage, while serum creatinine, fasting blood sugar (FBS), proteinuria, and blood pressure were evaluated at baseline, 3 and 6 months later. \u0000Results: The mean age of participants was 62.20 (± 4.45) years and 50% of them were females. Study indices including serum creatinine (P: 0.001), estimated glomerular filtration rate (eGFR) (P: 0.001), FBS (P: 0.001), HgA1c (P: 0.001), proteinuria (P: 0.001), and blood pressure (P: 0.001) reduced significantly over time in both groups. After adjustment for potential confounders, Empagliflozin reduced the level of serum creatinine independent of other factors. \u0000Conclusion: Empagliflozin significantly reduces the level of serum creatinine compared to Linagliptin in patients with T2DM and chronic renal failure.","PeriodicalId":33205,"journal":{"name":"Iranian Journal of Diabetes and Obesity","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141336298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-15DOI: 10.18502/ijdo.v16i2.15711
Debanjan Roy, Gunjan Gayen, S. Begum, Sandip Ghosh, Sucheto Talukder, Arisha Sarkar, S. Aich
Objective: Bullous pemphigoid is a rare autoimmune skin disorder characterized by blistering, urticarial lesions, which are sometimes associated with adverse drug reactions. Vildagliptin is an oral anti-diabetic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme Materials and Methods: A 75-year-old female with a known case of type 2 Diabetes Mellitus, hypertension, and hypothyroidism for the last 10 years presented with pruriginous tense bullous skin lesions over her both palms and soles. There was no mucosal involvement. Further interrogation revealed that she started taking Vildagliptin 5 days ago which was prescribed due to high levels of post-prandial blood sugar level despite already intake of Glimepiride-4 mg and Metformin-3 gm. Results: Vildagliptin was immediately advised to be stopped. She was treated with antihistamines, steroids, and conservative management which led to remission of the blisters Conclusion: Vildagliptin is the probable causative drug for developing bullous pemphigoid skin lesion which shows temporal association in this case as other concomitant drugs has no direct correlation. Therefore physicians must be aware of this rare life-threatening side effect of this medicine and advice patients to visit the hospital even the slightest cutaneous manifestation. Bullous pemphigoid can result in fatal life-threatening conditions if not treated early.
{"title":"Vildagliptin-Associated Bullous Pemphigoid: A Case Report","authors":"Debanjan Roy, Gunjan Gayen, S. Begum, Sandip Ghosh, Sucheto Talukder, Arisha Sarkar, S. Aich","doi":"10.18502/ijdo.v16i2.15711","DOIUrl":"https://doi.org/10.18502/ijdo.v16i2.15711","url":null,"abstract":"Objective: Bullous pemphigoid is a rare autoimmune skin disorder characterized by blistering, urticarial lesions, which are sometimes associated with adverse drug reactions. Vildagliptin is an oral anti-diabetic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme \u0000Materials and Methods: A 75-year-old female with a known case of type 2 Diabetes Mellitus, hypertension, and hypothyroidism for the last 10 years presented with pruriginous tense bullous skin lesions over her both palms and soles. There was no mucosal involvement. Further interrogation revealed that she started taking Vildagliptin 5 days ago which was prescribed due to high levels of post-prandial blood sugar level despite already intake of Glimepiride-4 mg and Metformin-3 gm. \u0000Results: Vildagliptin was immediately advised to be stopped. She was treated with antihistamines, steroids, and conservative management which led to remission of the blisters \u0000Conclusion: Vildagliptin is the probable causative drug for developing bullous pemphigoid skin lesion which shows temporal association in this case as other concomitant drugs has no direct correlation. Therefore physicians must be aware of this rare life-threatening side effect of this medicine and advice patients to visit the hospital even the slightest cutaneous manifestation. Bullous pemphigoid can result in fatal life-threatening conditions if not treated early.","PeriodicalId":33205,"journal":{"name":"Iranian Journal of Diabetes and Obesity","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141335981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-15DOI: 10.18502/ijdo.v16i2.15707
Mohsen Gholinataj Jelodar, S. Mirzaei, Majid Haji Maghsoudi
Objective: Diabetic patients with COVID-19 are at the higher risk of clinical complications and intensive care unit (ICU) admission. There is limited information available on the risk factors of mortality in diabetic patients with COVID-19 admitted to the ICUs. The aim of this study was identifying the mortality risk factors in diabetic patients with COVID-19 who are admitted to the ICU. Materials and Methods: In this study, we conducted a descriptive-analytical observational analysis on 391 patients admitted to the ICU for 18 months. We assessed the demographic, clinical, pharmaceutical, laboratory and imaging data of diabetic patients and statistically analyzed them to identify mortality risk factors. Results: The study found 156 (39.89%) diabetic out of 391 patients. The group of diabetic patients had significantly higher rates of endotracheal intubation (P< 0.001), mortality (P< 0.001), and complications during hospitalization due to COVID-19, including secondary bacterial infections (P = 0.005), venous thrombosis (P = 0.008), and gastrointestinal bleeding (P = 0.011), compared to the nondiabetic patient. Conclusion: Patients with diabetes who also have COVID-19 tend to experience more severe clinical outcomes and a higher mortality rate when admitted to the intensive care unit. The likelihood of mortality in these patients is closely associated with factors such as stroke occurrence, oxygenation levels, and the presence of secondary infections at the time of admission.
{"title":"Predictors of Mortality among Intensive Care Unit (ICU) Hospitalized Diabetic Patients with COVID-19","authors":"Mohsen Gholinataj Jelodar, S. Mirzaei, Majid Haji Maghsoudi","doi":"10.18502/ijdo.v16i2.15707","DOIUrl":"https://doi.org/10.18502/ijdo.v16i2.15707","url":null,"abstract":"Objective: Diabetic patients with COVID-19 are at the higher risk of clinical complications and intensive care unit (ICU) admission. There is limited information available on the risk factors of mortality in diabetic patients with COVID-19 admitted to the ICUs. The aim of this study was identifying the mortality risk factors in diabetic patients with COVID-19 who are admitted to the ICU. \u0000Materials and Methods: In this study, we conducted a descriptive-analytical observational analysis on 391 patients admitted to the ICU for 18 months. We assessed the demographic, clinical, pharmaceutical, laboratory and imaging data of diabetic patients and statistically analyzed them to identify mortality risk factors. \u0000Results: The study found 156 (39.89%) diabetic out of 391 patients. The group of diabetic patients had significantly higher rates of endotracheal intubation (P< 0.001), mortality (P< 0.001), and complications during hospitalization due to COVID-19, including secondary bacterial infections (P = 0.005), venous thrombosis (P = 0.008), and gastrointestinal bleeding (P = 0.011), compared to the nondiabetic patient. \u0000Conclusion: Patients with diabetes who also have COVID-19 tend to experience more severe clinical outcomes and a higher mortality rate when admitted to the intensive care unit. The likelihood of mortality in these patients is closely associated with factors such as stroke occurrence, oxygenation levels, and the presence of secondary infections at the time of admission.","PeriodicalId":33205,"journal":{"name":"Iranian Journal of Diabetes and Obesity","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141337540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-15DOI: 10.18502/ijdo.v16i2.15712
T. Yahaya, Israel Obaroh, Umar Magaji, C. Obadiah, D. Anyebe, U. Shemishere
Numerous suspect genes associated with type 1 diabetes mellitus (T1DM) have been identified, suggesting a need to focus on the disease's causal genes and mechanisms. This necessitates an update to raise public awareness. This review articulates genes with mutations that predispose individuals to T1DM. We conducted a comprehensive search of academic databases, including Web of Science, Scopus, PubMed, and Google Scholar, for relevant materials. Available information indicates that at least 70 genes are suspected in the pathogenesis of T1DM. However, the most frequently implicated genes include human leukocyte antigen (HLA), insulin (INS), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and protein tyrosine phosphatase non-receptor type 22 (PTPN22). Mutations or variants in these genes may lead to insulin insufficiency and, consequently, T1DM by tricking immune cells, such as T-cells and B-cells, into attacking self-antigens and triggering the autoimmunity of beta cells. Furthermore, this pathophysiology can be mediated through aberrant epigenetic modifications, including DNA methylation, histone post-translational modifications, and noncoding RNAs, in the mentioned genes. Some of these pathophysiologies are gene-specific and may have an epigenetic origin that is reversible. In the event of an epigenetic origin, a treatment for T1DM that addresses the causal genes or reverses epigenetic changes and their mechanisms could yield improved outcomes. Medical professionals are encouraged to design therapeutic regimens that specifically target the mentioned genes and address the identified epigenetic alterations in individuals expressing such etiologies.
已发现许多与 1 型糖尿病（T1DM）相关的可疑基因，这表明有必要关注该疾病的致病基因和机制。因此有必要进行更新，以提高公众的认识。本综述阐述了易患 T1DM 的突变基因。我们对学术数据库（包括 Web of Science、Scopus、PubMed 和 Google Scholar）进行了全面搜索，以查找相关资料。现有资料表明，至少有 70 个基因被怀疑与 T1DM 的发病机制有关。不过，最常涉及的基因包括人类白细胞抗原（HLA）、胰岛素（INS）、细胞毒性 T 淋巴细胞相关抗原 4（CTLA-4）和蛋白酪氨酸磷酸酶非受体 22 型（PTPN22）。这些基因的突变或变异可能会诱使免疫细胞（如 T 细胞和 B 细胞）攻击自身抗原，引发β细胞的自身免疫，从而导致胰岛素分泌不足，进而引发 T1DM。此外，这种病理生理学可通过上述基因的异常表观遗传修饰（包括 DNA 甲基化、组蛋白翻译后修饰和非编码 RNA）来介导。这些病理生理现象中有些是基因特异性的，其表观遗传起源可能是可逆的。如果是表观遗传引起的，针对致病基因或逆转表观遗传变化及其机制的 T1DM 治疗方法可以改善疗效。我们鼓励医学专家设计专门针对上述基因的治疗方案，并解决已确定的表观遗传学改变，以治疗表达此类病因的个体。
{"title":"Genetic and Epigenetic Etiologies of Type 1 Diabetes Mellitus","authors":"T. Yahaya, Israel Obaroh, Umar Magaji, C. Obadiah, D. Anyebe, U. Shemishere","doi":"10.18502/ijdo.v16i2.15712","DOIUrl":"https://doi.org/10.18502/ijdo.v16i2.15712","url":null,"abstract":"Numerous suspect genes associated with type 1 diabetes mellitus (T1DM) have been identified, suggesting a need to focus on the disease's causal genes and mechanisms. This necessitates an update to raise public awareness. This review articulates genes with mutations that predispose individuals to T1DM. We conducted a comprehensive search of academic databases, including Web of Science, Scopus, PubMed, and Google Scholar, for relevant materials. Available information indicates that at least 70 genes are suspected in the pathogenesis of T1DM. However, the most frequently implicated genes include human leukocyte antigen (HLA), insulin (INS), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and protein tyrosine phosphatase non-receptor type 22 (PTPN22). Mutations or variants in these genes may lead to insulin insufficiency and, consequently, T1DM by tricking immune cells, such as T-cells and B-cells, into attacking self-antigens and triggering the autoimmunity of beta cells. Furthermore, this pathophysiology can be mediated through aberrant epigenetic modifications, including DNA methylation, histone post-translational modifications, and noncoding RNAs, in the mentioned genes. Some of these pathophysiologies are gene-specific and may have an epigenetic origin that is reversible. In the event of an epigenetic origin, a treatment for T1DM that addresses the causal genes or reverses epigenetic changes and their mechanisms could yield improved outcomes. Medical professionals are encouraged to design therapeutic regimens that specifically target the mentioned genes and address the identified epigenetic alterations in individuals expressing such etiologies.","PeriodicalId":33205,"journal":{"name":"Iranian Journal of Diabetes and Obesity","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141336830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-15DOI: 10.18502/ijdo.v16i2.15710
Fateme Sefid, Kimia Monshizadeh, G. Azamirad, Mohammad Yahya Vahidi Mehrjardi
Objective: The VEGF function blockage effectively reduces the progression of diabetic retinopathy. Ranibizumab and bevacizumab are some anti-VEGF monoclonal antibodies (mAb). Considering the importance of affinity maturation of ranibizumab, we aimed to find the essential amino acids of the ranibizumab antibody (Ab). Materials and Methods: We tried to find the important amino acids of this antibody via Paratome, Meta-PPISP, and the WESA web server. Subsequently, these amino acids were mutated to improve the binding affinity of the Ab variants to antigen (Ag). In this regard, the ranibizumab anti-VEGF-A was mutated. The structural docking prediction of the ranibizumab-VEGF-A complex was used for the design and validation of ranibizumab with a higher affinity for binding to VEGF-A. Finally, we measured the binding affinity of Ab variants to Ag by computational docking. Results: Bioinformatic analyzes such as molecular docking and dynamics showed that several mutant variants successfully improved the properties of Ab binding compared to the wild-type Ab. Conclusion: Consistent with the use of anti-VEGF monoclonal antibodies in the treatment of diabetic retinopathy, the mutant variants of ranibizumab may be potential candidates for stronger affinity binding to VEGF, which may affect the specificity and sensitivity of the antibody.
{"title":"Antibody Engineering to Enhancement of Ranibizumab Binding Affinity for the Prevention and Treatment of Diabetic Retinopathy","authors":"Fateme Sefid, Kimia Monshizadeh, G. Azamirad, Mohammad Yahya Vahidi Mehrjardi","doi":"10.18502/ijdo.v16i2.15710","DOIUrl":"https://doi.org/10.18502/ijdo.v16i2.15710","url":null,"abstract":"Objective: The VEGF function blockage effectively reduces the progression of diabetic retinopathy. Ranibizumab and bevacizumab are some anti-VEGF monoclonal antibodies (mAb). Considering the importance of affinity maturation of ranibizumab, we aimed to find the essential amino acids of the ranibizumab antibody (Ab). \u0000Materials and Methods: We tried to find the important amino acids of this antibody via Paratome, Meta-PPISP, and the WESA web server. Subsequently, these amino acids were mutated to improve the binding affinity of the Ab variants to antigen (Ag). In this regard, the ranibizumab anti-VEGF-A was mutated. The structural docking prediction of the ranibizumab-VEGF-A complex was used for the design and validation of ranibizumab with a higher affinity for binding to VEGF-A. Finally, we measured the binding affinity of Ab variants to Ag by computational docking. \u0000Results: Bioinformatic analyzes such as molecular docking and dynamics showed that several mutant variants successfully improved the properties of Ab binding compared to the wild-type Ab. \u0000Conclusion: Consistent with the use of anti-VEGF monoclonal antibodies in the treatment of diabetic retinopathy, the mutant variants of ranibizumab may be potential candidates for stronger affinity binding to VEGF, which may affect the specificity and sensitivity of the antibody.","PeriodicalId":33205,"journal":{"name":"Iranian Journal of Diabetes and Obesity","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141337542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-28DOI: 10.18502/ijdo.v16i1.15243
Mohammad Hasan Lotfi, Mohammad Mehdi Ahmadi Faraz, Nasim Namiranian, Roohollah Arab, Maesomeh Dashtabadi, Hasan Zare Khormizi
Objective: Currently, spiritual health is the most important dimension related to adaptation in chronic diseases.The aim of the present study is review of the role of spiritual health in patients with type II diabetes mellitus.Improvement of spiritual health leads to better adaptation, increasing psychological well-being, decreasing mood symptoms and improvement of life quality in patients with type 2 diabetes mellitus .Therefore, it is suggested that the treatment of diabetes must include spiritual care and interventions.
本研究旨在回顾精神健康在 II 型糖尿病患者中的作用：目前，精神健康是与慢性病适应相关的最重要的维度。本研究的目的是回顾精神健康在 II 型糖尿病患者中的作用。改善精神健康会使 2 型糖尿病患者更好地适应，增加心理幸福感，减少情绪症状，提高生活质量。因此，建议糖尿病治疗必须包括精神护理和干预。
{"title":"A Review About the Role of Spiritual Health in Type 2 Diabetes Mellitus People","authors":"Mohammad Hasan Lotfi, Mohammad Mehdi Ahmadi Faraz, Nasim Namiranian, Roohollah Arab, Maesomeh Dashtabadi, Hasan Zare Khormizi","doi":"10.18502/ijdo.v16i1.15243","DOIUrl":"https://doi.org/10.18502/ijdo.v16i1.15243","url":null,"abstract":"\u0000 \u0000 \u0000Objective: Currently, spiritual health is the most important dimension related to adaptation in chronic diseases.The aim of the present study is review of the role of spiritual health in patients with type II diabetes mellitus.Improvement of spiritual health leads to better adaptation, increasing psychological well-being, decreasing mood symptoms and improvement of life quality in patients with type 2 diabetes mellitus .Therefore, it is suggested that the treatment of diabetes must include spiritual care and interventions. \u0000 \u0000 \u0000","PeriodicalId":33205,"journal":{"name":"Iranian Journal of Diabetes and Obesity","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140372970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-28DOI: 10.18502/ijdo.v16i1.15235
Amineh Jalali, Reza Pourhosein, Ahmad Alipour, Gholam Ali Afrooz
Objective: Diabetes is a chronic metabolic disorder that can be exacerbated by stress, poor compliance and self-care practices. This study investigated the effects of self-care training combined with stress management on treatment adherence in type 2 diabetes mellitus (T2DM) people. Materials and Methods: This is a randomized clinical trial with repeated measures. The study sample included 30 T2DM who were purposively selected among the eligible members of the Kerman Diabetes Association. The participants were randomized to the experimental group (stress management based on cognitive-behavioral therapy and self-care training) (n=15) and the control group (no intervention) (n=15). Both groups completed the Medanlo Treatment Adherence Questionnaire at the pretest, posttest, and follow-up time points. Data were analyzed statistically using ANOVA. Results: The post-test and follow-up mean scores of treatment adherence significantly increased in the experimental group compared with the control group (P< 0.001). In addition, the results demonstrated that treatment adherence improved in follow-up (P< 0.001). Conclusion: According to the study results, psychological training should be integrated with self-care training to achieve long lasting treatment adherence in T2DM people.
{"title":"Effects of Self-Care Training Combined with Stress Management on Treatment Adherence in Type 2 Diabetes People","authors":"Amineh Jalali, Reza Pourhosein, Ahmad Alipour, Gholam Ali Afrooz","doi":"10.18502/ijdo.v16i1.15235","DOIUrl":"https://doi.org/10.18502/ijdo.v16i1.15235","url":null,"abstract":"\u0000 \u0000 \u0000Objective: Diabetes is a chronic metabolic disorder that can be exacerbated by stress, poor compliance and self-care practices. This study investigated the effects of self-care training combined with stress management on treatment adherence in type 2 diabetes mellitus (T2DM) people. \u0000Materials and Methods: This is a randomized clinical trial with repeated measures. The study sample included 30 T2DM who were purposively selected among the eligible members of the Kerman Diabetes Association. The participants were randomized to the experimental group (stress management based on cognitive-behavioral therapy and self-care training) (n=15) and the control group (no intervention) (n=15). Both groups completed the Medanlo Treatment Adherence Questionnaire at the pretest, posttest, and follow-up time points. Data were analyzed statistically using ANOVA. \u0000Results: The post-test and follow-up mean scores of treatment adherence significantly increased in the experimental group compared with the control group (P< 0.001). In addition, the results demonstrated that treatment adherence improved in follow-up (P< 0.001). \u0000Conclusion: According to the study results, psychological training should be integrated with self-care training to achieve long lasting treatment adherence in T2DM people. \u0000 \u0000 \u0000","PeriodicalId":33205,"journal":{"name":"Iranian Journal of Diabetes and Obesity","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140370783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-28DOI: 10.18502/ijdo.v16i1.15234
Mohammad Reza Aqebati, Jafar Shabani
Objective: This study was conducted to investigate the effectiveness of mindfulness group training based on stress reduction on emotional self-regulation and self-care in type 2 diabetes people - Esfrain 2023. Materials and Methods: This is an experimental research with a pre-test and post-test method and a control group. The statistical society included all type 2 diabetes people in Esfrain city, of whom 36 people were selected as the study sample. The participants were simple random placed in an experimental group and a control group. The experimental group received mindfulness group education based on stress reduction during eight 2-h sessions over 8 weeks, whereas the control group received no education. Before and after the education sessions, the two groups completed Hoffman and Kashdan’s (2010) emotional self-regulation questionnaire and Tobert and Glasso’s (2000) self-care questionnaire. Data were analyzed using the multivariate analysis of covariance test. Results: The results showed that mindfulness group training based on stress reduction can improve emotional self-regulation scores and life expectancy in patients with type 2 diabetes(P: 0.0005). Conclusion: According to the results of the research, mindfulness training based on stress reduction is suggested to diabetic patients as a complementary treatment with the aim of improving the level of emotional self-regulation and self-care.
{"title":"Effectiveness of Mindfulness Group Training Based on Stress Reduction on Emotional Self-Regulation and Self-Care in Diabetes Type 2","authors":"Mohammad Reza Aqebati, Jafar Shabani","doi":"10.18502/ijdo.v16i1.15234","DOIUrl":"https://doi.org/10.18502/ijdo.v16i1.15234","url":null,"abstract":"\u0000 \u0000 \u0000Objective: This study was conducted to investigate the effectiveness of mindfulness group training based on stress reduction on emotional self-regulation and self-care in type 2 diabetes people - Esfrain 2023. \u0000Materials and Methods: This is an experimental research with a pre-test and post-test method and a control group. The statistical society included all type 2 diabetes people in Esfrain city, of whom 36 people were selected as the study sample. The participants were simple random placed in an experimental group and a control group. The experimental group received mindfulness group education based on stress reduction during eight 2-h sessions over 8 weeks, whereas the control group received no education. Before and after the education sessions, the two groups completed Hoffman and Kashdan’s (2010) emotional self-regulation questionnaire and Tobert and Glasso’s (2000) self-care questionnaire. Data were analyzed using the multivariate analysis of covariance test. \u0000Results: The results showed that mindfulness group training based on stress reduction can improve emotional self-regulation scores and life expectancy in patients with type 2 diabetes(P: 0.0005). \u0000Conclusion: According to the results of the research, mindfulness training based on stress reduction is suggested to diabetic patients as a complementary treatment with the aim of improving the level of emotional self-regulation and self-care. \u0000 \u0000 \u0000","PeriodicalId":33205,"journal":{"name":"Iranian Journal of Diabetes and Obesity","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140369024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-28DOI: 10.18502/ijdo.v16i1.15237
Akbar Karimy, Yaser Kazemzadeh, M. Eizadi, Saeid Sedaghaty, Sepideh Ghotnian
Objective: Hepatic glucose release is greatly increased in the presence of obesity and related diseases. The research objective was to explore the impact of high intensity interval training (HIIT) on TCF7L2 gene expression in hepatocytes of obese rats. Materials and Methods: Out of 21 male Wistar rats aged 10 weeks years (220±10 g), obesity was induced in 14 rats by 8-week high-fat diet. The rats were then divided into normal (n=7), obese control (n=7), and HIIT obese (n=7) groups. Rats in the HIIT group completed 8 weeks of HIIT/5 days weekly, whereas the other groups were inactive. After intervention, TCF7L2 gene expression in hepatocytes, insulin resistance and glucose compared using ANOVA /Tukey’s post hoc test between groups by SPSS-22. Results: Obesity induction led to a significant decrease in TCF7L2 gene expression (P: 0.011) and an increase in blood glucose (P: 0.009) and insulin resistance (P: 0.019) compared with the normal group (P< 0.001). On the other hand, interval training led to a significant increase in TCF7L2 gene expression (P: 0.029) and a decrease in blood glucose (P< 0.001) and insulin resistance (P< 0.001) in the obese group compared with the control group. Conclusion: The observed enhancement in fasting blood glucose levels among obese rats could be linked to increased TCF7L2 gene expression in liver cells, which appears to be a response to interval training intervention. Nevertheless, understanding the main mechanisms responsible for observed changes requires further studies in this field.
{"title":"Effect of High-Intensity Interval Training on TCF7L2 Gene Expression in Hepatocytes of Obese Rats","authors":"Akbar Karimy, Yaser Kazemzadeh, M. Eizadi, Saeid Sedaghaty, Sepideh Ghotnian","doi":"10.18502/ijdo.v16i1.15237","DOIUrl":"https://doi.org/10.18502/ijdo.v16i1.15237","url":null,"abstract":"\u0000 \u0000 \u0000Objective: Hepatic glucose release is greatly increased in the presence of obesity and related diseases. The research objective was to explore the impact of high intensity interval training (HIIT) on TCF7L2 gene expression in hepatocytes of obese rats. \u0000Materials and Methods: Out of 21 male Wistar rats aged 10 weeks years (220±10 g), obesity was induced in 14 rats by 8-week high-fat diet. The rats were then divided into normal (n=7), obese control (n=7), and HIIT obese (n=7) groups. Rats in the HIIT group completed 8 weeks of HIIT/5 days weekly, whereas the other groups were inactive. After intervention, TCF7L2 gene expression in hepatocytes, insulin resistance and glucose compared using ANOVA /Tukey’s post hoc test between groups by SPSS-22. \u0000Results: Obesity induction led to a significant decrease in TCF7L2 gene expression (P: 0.011) and an increase in blood glucose (P: 0.009) and insulin resistance (P: 0.019) compared with the normal group (P< 0.001). On the other hand, interval training led to a significant increase in TCF7L2 gene expression (P: 0.029) and a decrease in blood glucose (P< 0.001) and insulin resistance (P< 0.001) in the obese group compared with the control group. \u0000Conclusion: The observed enhancement in fasting blood glucose levels among obese rats could be linked to increased TCF7L2 gene expression in liver cells, which appears to be a response to interval training intervention. Nevertheless, understanding the main mechanisms responsible for observed changes requires further studies in this field. \u0000 \u0000 \u0000","PeriodicalId":33205,"journal":{"name":"Iranian Journal of Diabetes and Obesity","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140369858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：